Karyopharm Therapeutics Inc (KPTI) 27.12 $KPTI
Karyopharm to Present at Leerink Partners Global Healthcare Conference
GlobeNewswire - Thu Feb 05, 10:00AM CST
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that Michael G. Kauffman, MD, PhD, Chief Executive Officer of Karyopharm, is scheduled to present at the Leerink Partners Global Healthcare Conference in New York on Thursday, February 12, 2015 at 3:30 p.m. ET.
KPTI: 27.12 (-0.13)
Hematological Malignancies: Multiple Myeloma (MM) Market Report 2015
M2 - Tue Feb 03, 5:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/rsh8ph/hematological) has announced the addition of the "Hematological Malignancies: Multiple Myeloma (MM) " report to their offering. While targeting unmet needs in the treatment of hematological malignancies/ cancer through innovative drug development strategies have witnessed favorable outcomes, the specific choice of the therapies is dependent on the identification of important genomic alterations in cancerous cells that allow for the tumor's sub classification. Over the past decade, Proteasome inhibitor and the immunomodulatory drugs have become the cornerstone of treatment for pts with Multiple Myeloma (MM) resulting in improved survival. However, eventually all pts relapse and use of modern diagnosis will enable risk stratification to help distinguish pts along the spectrum of the condition. This can aid in the selection of new treatment options for Relapsed/ Refractory Multiple Myeloma (RRMM) to further improve survival and quality of life of each patient. Two new drugs have successfully fulfilled this need - POMALYST/ IMNOVID (pomalidomide - POM, Celgene, approved) and Kyprolis (carfilzomib-CFZ, Amgen/ Ono Pharma - JP, approved). While novel targets address unmet need, the pertinent Question remains - is there a need for further improvement? What should be the diagnosis criteria and/or novel imaging / diagnostic tools that can further stratify a pts' risk profile? Precision medicine approaches in myeloma require fast, robust, and practicable molecular diagnostic tools, and the current diagnostic standard iFISH (interphase fluorescence in situ hybridization) is unable to fulfill any of these criteria. Integration of Diagnostics into therapeutic products/ industry has potential to improve trial design, enhance safety profile, enhance therapeutic efficacy, accelerate trial outcome, and increase commercial success. However, there are few hurdles which are also associated with new model, such as understanding the diagnostic industry, complex trial execution, seeking a 'right' diagnostic partner, managing the co-development process, regulatory uncertainty around companion diagnostics and intellectual property issues. This report highlights the emerging new treatments in RRMM /NDMM, which includes combination of small molecules and biologics, and novel approach of molecular analysis of MM. This report also provides M&A deals in the diagnostic, cancer area along with growing market opportunities. Furthermore, the competitive landscape of NDMM and RRMM is also highlighted. The rivalry prevalent in the global onco-diagnostic and therapeutic MM market is quite fierce with numerous local and global players contenting for the market share. On the global diagnostic front, the key players are Roche, Abbott Diagnostics, and Illumina; and in Tx area, the key players are Celgene, Takeda pharma, Amgen, Novartis, and JNJ. Key Topics Covered: 1. Executive Summary 2. Disease Overview, Diagnosis, and Current Treatment 3. Diagnostic Tools for Multiple Myeloma 4. M&A Deals and Market Opportunity in Diagnostic Space 5. Current Therapies 6. Novel Targets 7. Clinical Milestones 8. Launch Timeline and Commercial Opportunity of Late-Stage Pipeline 9. M&A/ Licensing Deals and Unpartnered Product Opportunities Companies Mentioned - Abbott - Affymetrix - AgenaBio - Altor Bioscience - Amgen - Array Biopharma - Astex pharma (now Otsuka pharma) - BMS - Biotest pharma - Cancer Genetics Inc - Celgene - CureTech - GSK - Illumina - Immunogen - Innate Pharma - Innate Pharma - JNJ - Karyopharm Therapeutics - Lilly - Merck - MorphoSys - Mundipharma - NeoGenomics - Novartis - Pharmacyclics - Regulus Therapeutics - Rosetta Genomics - Sequenta - Takeda Pharma For more information visit http://www.researchandmarkets.com/research/rs...atological
MRK: 58.81 (-0.07), AMGN: 153.48 (+0.30), RGLS: 16.85 (-0.13), CGIX: 7.07 (unch), NVS: 102.20 (-0.17), KPTI: 27.12 (-0.13), CELGZ: 3.17 (-0.04)
Commit To Purchase Karyopharm Therapeutics At $22.50, Earn 19.6% Annualized Using Options
at The Street - Mon Jan 26, 10:44AM CST
Investors considering a purchase of Karyopharm Therapeutics Inc shares, but cautious about paying the going market price of $28.94/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting...
KPTI: 27.12 (-0.13)
InsiderInsights.com Daily Round Up 1/14/15: OPK, REN, VEEV, CO
InsiderInsights - at Seeking Alpha - Thu Jan 15, 10:41AM CST
AFAM: 30.88 (+0.37), BBW: 20.94 (+0.14), BBY: 39.11 (-0.08), GOOG: 549.01 (+6.08), VEEV: 30.12 (+0.17), BBBY: 77.91 (-0.49), OPK: 13.80 (-0.28), REN: 1.14 (unch), AVHI: 15.16 (+0.04), GOOGL: 551.16 (+5.15), SIX: 45.11 (-0.05), BNCL: 11.54 (-0.02), CO: 4.75 (-0.06), GRPN: 7.97 (+0.51), SPN: 21.72 (+0.89), ALCO: 45.40 (+1.44), KPTI: 27.12 (-0.13), CRM: 62.85 (+1.59)
Karyopharm receives US FDA's orphan designation for selinexor for multiple myeloma
M2 - Fri Jan 09, 7:25AM CST
Pharmaceutical company Karyopharm Therapeutics (NasdaqGS:KPTI) revealed on Thursday that its lead drug candidate, selinexor, has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma.
KPTI: 27.12 (-0.13)
Karyopharm lead product an Orphan Drug for multiple myeloma
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 9:07AM CST
KPTI: 27.12 (-0.13)
Karyopharm Announces Orphan Designation Granted by FDA for Selinexor (KPT-330) in Multiple Myeloma
GlobeNewswire - Thu Jan 08, 7:50AM CST
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that its lead drug candidate, selinexor (KPT-330), has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma. Orphan designation was created to encourage the development of drugs which may provide significant benefit to patients suffering from rare diseases.
KPTI: 27.12 (-0.13)
Karyopharm to Present at J.P. Morgan 33rd Annual Healthcare Conference
GlobeNewswire - Wed Jan 07, 3:42PM CST
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that Michael G. Kauffman, MD, PhD, Chief Executive Officer of Karyopharm, is scheduled to present at the J.P. Morgan 33 Annual Healthcare Conference in San Francisco on Tuesday, January 13, 2015 at 2:30 p.m. PST.
JPM: 59.67 (+0.10), KPTI: 27.12 (-0.13)
Karyopharm Therapeutics prices public offering at USD33.00 per share
M2 - Wed Jan 07, 6:16AM CST
Pharmaceutical company Karyopharm Therapeutics (NasdaqGS:KPTI) said on Wednesday that it has priced its public offering of 3,000,000 shares of its common stock at USD33.00 per share before underwriting discounts.
KPTI: 27.12 (-0.13)
Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Tue Jan 06, 10:55PM CST
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) today announced the pricing of its underwritten public offering of 3,000,000 shares of its common stock at a price of $33.00 per share before underwriting discounts. Karyopharm is selling 2,950,000 shares of its common stock in this offering, and certain existing stockholders are selling 50,000 shares of common stock in this offering. Karyopharm will not receive any proceeds from the sale of shares by the selling stockholders. In addition, Karyopharm has granted to the underwriters a 30-day option to purchase up to an additional 450,000 shares of its common stock, at the public offering price, less the underwriting discount.
KPTI: 27.12 (-0.13)
Karyopharm Therapeutics to issue public offering of 3m common shares
M2 - Tue Jan 06, 4:39AM CST
Pharmaceutical company Karyopharm Therapeutics (NasdaqGS:KPTI) said on Monday that it plans to start an underwritten public offering of 3,000,000 shares of its common stock.
KPTI: 27.12 (-0.13)
Karyopharm commences secondary offering
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 4:18PM CST
KPTI: 27.12 (-0.13)
Karyopharm Therapeutics Announces Proposed Public Offering of Common Stock
GlobeNewswire - Mon Jan 05, 3:44PM CST
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) today announced that it has commenced an underwritten public offering of 3,000,000 shares of its common stock. The offering is expected to consist of 2,950,000 shares to be offered by Karyopharm and 50,000 shares to be offered by existing stockholders. Karyopharm will not receive any proceeds from the sale of shares by the selling stockholders. In addition, Karyopharm intends to grant the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
JPM: 59.67 (+0.10), KPTI: 27.12 (-0.13)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), FPRX: 24.63 (+0.63), ZFGN: 39.06 (+0.92), CRIS: 3.23 (+0.25), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Karyopharm Announces Addition to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 8:06AM CST
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced today that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq:NBI). The addition to the NASDAQ Biotechnology Index will become effective upon market open on Monday, December 22, 2014.
IBB: 323.46 (+3.04), KPTI: 27.12 (-0.13)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), ZGNX: 1.43 (+0.05), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), NDAQ: 49.48 (-0.27), FPRX: 24.63 (+0.63), CRIS: 3.23 (+0.25), ZFGN: 39.06 (+0.92), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Dec 11, 11:45AM CST
SD: 2.09 (+0.14), FRO: 2.96 (+0.07), ABCO: 53.69 (+0.32), ZAZA: 2.17 (+0.08), JMEI: 12.67 (+0.31), SGMO: 15.40 (+0.14), TGTX: 13.13 (-0.19), MEI: 39.40 (+0.22), WLT: 1.09 (+0.05), NSPR: 0.70 (-0.05), VII: 1.47 (-0.02), CVTI: 29.64 (-0.13), MEIP: 5.00 (-0.04), ALDR: 26.06 (+0.18), CALA: 16.11 (+0.62), CGG: 6.86 (+0.06), SPP: 1.36 (unch), DSCO: 1.43 (+0.05), KPTI: 27.12 (-0.13), HBOS: 24.84 (+0.14)
T-Cell Lymphomas - Pipeline Review, H2 2014
M2 - Thu Dec 11, 3:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/2wvfhz/tcell_lymphomas) has announced the addition of the "T-Cell Lymphomas - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for T-Cell Lymphomas, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for T-Cell Lymphomas and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for T-Cell Lymphomas - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding T-Cell Lymphomas pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - arGEN-X - Bristol-Myers Squibb - Celgene - Cell Medica - Infinity Pharmaceuticals - Karyopharm Therapeutics - Kyowa Hakko Kirin - Nippon Kayaku - Novartis - Ono Pharmaceutical - Onyx Pharmaceuticals - Pharma Mar - Pharmacyclics - Seattle Genetics - Sigma-Tau For more information visit http://www.researchandmarkets.com/research/2w..._lymphomas
INFI: 15.13 (+0.55), BMY: 60.04 (+0.56), NVS: 102.20 (-0.17), KPTI: 27.12 (-0.13), CELGZ: 3.17 (-0.04)
Weakness Seen in Karyopharm Therapeutics (KPTI): Stock Tanks 10% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 7:49AM CST
Make sure to keep an eye on Karyopharm Therapeutics going forward to see if this recent slump will continue, as the earnings picture definitely suggests that this might be the case.
KPTI: 27.12 (-0.13)
Karyopharm to Present at Leerink Partners Global Healthcare Conference
GlobeNewswire - Thu Feb 05, 10:00AM CST
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that Michael G. Kauffman, MD, PhD, Chief Executive Officer of Karyopharm, is scheduled to present at the Leerink Partners Global Healthcare Conference in New York on Thursday, February 12, 2015 at 3:30 p.m. ET.
KPTI: 27.12 (-0.13)
Hematological Malignancies: Multiple Myeloma (MM) Market Report 2015
M2 - Tue Feb 03, 5:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/rsh8ph/hematological) has announced the addition of the "Hematological Malignancies: Multiple Myeloma (MM) " report to their offering. While targeting unmet needs in the treatment of hematological malignancies/ cancer through innovative drug development strategies have witnessed favorable outcomes, the specific choice of the therapies is dependent on the identification of important genomic alterations in cancerous cells that allow for the tumor's sub classification. Over the past decade, Proteasome inhibitor and the immunomodulatory drugs have become the cornerstone of treatment for pts with Multiple Myeloma (MM) resulting in improved survival. However, eventually all pts relapse and use of modern diagnosis will enable risk stratification to help distinguish pts along the spectrum of the condition. This can aid in the selection of new treatment options for Relapsed/ Refractory Multiple Myeloma (RRMM) to further improve survival and quality of life of each patient. Two new drugs have successfully fulfilled this need - POMALYST/ IMNOVID (pomalidomide - POM, Celgene, approved) and Kyprolis (carfilzomib-CFZ, Amgen/ Ono Pharma - JP, approved). While novel targets address unmet need, the pertinent Question remains - is there a need for further improvement? What should be the diagnosis criteria and/or novel imaging / diagnostic tools that can further stratify a pts' risk profile? Precision medicine approaches in myeloma require fast, robust, and practicable molecular diagnostic tools, and the current diagnostic standard iFISH (interphase fluorescence in situ hybridization) is unable to fulfill any of these criteria. Integration of Diagnostics into therapeutic products/ industry has potential to improve trial design, enhance safety profile, enhance therapeutic efficacy, accelerate trial outcome, and increase commercial success. However, there are few hurdles which are also associated with new model, such as understanding the diagnostic industry, complex trial execution, seeking a 'right' diagnostic partner, managing the co-development process, regulatory uncertainty around companion diagnostics and intellectual property issues. This report highlights the emerging new treatments in RRMM /NDMM, which includes combination of small molecules and biologics, and novel approach of molecular analysis of MM. This report also provides M&A deals in the diagnostic, cancer area along with growing market opportunities. Furthermore, the competitive landscape of NDMM and RRMM is also highlighted. The rivalry prevalent in the global onco-diagnostic and therapeutic MM market is quite fierce with numerous local and global players contenting for the market share. On the global diagnostic front, the key players are Roche, Abbott Diagnostics, and Illumina; and in Tx area, the key players are Celgene, Takeda pharma, Amgen, Novartis, and JNJ. Key Topics Covered: 1. Executive Summary 2. Disease Overview, Diagnosis, and Current Treatment 3. Diagnostic Tools for Multiple Myeloma 4. M&A Deals and Market Opportunity in Diagnostic Space 5. Current Therapies 6. Novel Targets 7. Clinical Milestones 8. Launch Timeline and Commercial Opportunity of Late-Stage Pipeline 9. M&A/ Licensing Deals and Unpartnered Product Opportunities Companies Mentioned - Abbott - Affymetrix - AgenaBio - Altor Bioscience - Amgen - Array Biopharma - Astex pharma (now Otsuka pharma) - BMS - Biotest pharma - Cancer Genetics Inc - Celgene - CureTech - GSK - Illumina - Immunogen - Innate Pharma - Innate Pharma - JNJ - Karyopharm Therapeutics - Lilly - Merck - MorphoSys - Mundipharma - NeoGenomics - Novartis - Pharmacyclics - Regulus Therapeutics - Rosetta Genomics - Sequenta - Takeda Pharma For more information visit http://www.researchandmarkets.com/research/rs...atological
MRK: 58.81 (-0.07), AMGN: 153.48 (+0.30), RGLS: 16.85 (-0.13), CGIX: 7.07 (unch), NVS: 102.20 (-0.17), KPTI: 27.12 (-0.13), CELGZ: 3.17 (-0.04)
Commit To Purchase Karyopharm Therapeutics At $22.50, Earn 19.6% Annualized Using Options
at The Street - Mon Jan 26, 10:44AM CST
Investors considering a purchase of Karyopharm Therapeutics Inc shares, but cautious about paying the going market price of $28.94/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting...
KPTI: 27.12 (-0.13)
InsiderInsights.com Daily Round Up 1/14/15: OPK, REN, VEEV, CO
InsiderInsights - at Seeking Alpha - Thu Jan 15, 10:41AM CST
AFAM: 30.88 (+0.37), BBW: 20.94 (+0.14), BBY: 39.11 (-0.08), GOOG: 549.01 (+6.08), VEEV: 30.12 (+0.17), BBBY: 77.91 (-0.49), OPK: 13.80 (-0.28), REN: 1.14 (unch), AVHI: 15.16 (+0.04), GOOGL: 551.16 (+5.15), SIX: 45.11 (-0.05), BNCL: 11.54 (-0.02), CO: 4.75 (-0.06), GRPN: 7.97 (+0.51), SPN: 21.72 (+0.89), ALCO: 45.40 (+1.44), KPTI: 27.12 (-0.13), CRM: 62.85 (+1.59)
Karyopharm receives US FDA's orphan designation for selinexor for multiple myeloma
M2 - Fri Jan 09, 7:25AM CST
Pharmaceutical company Karyopharm Therapeutics (NasdaqGS:KPTI) revealed on Thursday that its lead drug candidate, selinexor, has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma.
KPTI: 27.12 (-0.13)
Karyopharm lead product an Orphan Drug for multiple myeloma
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 9:07AM CST
KPTI: 27.12 (-0.13)
Karyopharm Announces Orphan Designation Granted by FDA for Selinexor (KPT-330) in Multiple Myeloma
GlobeNewswire - Thu Jan 08, 7:50AM CST
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that its lead drug candidate, selinexor (KPT-330), has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma. Orphan designation was created to encourage the development of drugs which may provide significant benefit to patients suffering from rare diseases.
KPTI: 27.12 (-0.13)
Karyopharm to Present at J.P. Morgan 33rd Annual Healthcare Conference
GlobeNewswire - Wed Jan 07, 3:42PM CST
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that Michael G. Kauffman, MD, PhD, Chief Executive Officer of Karyopharm, is scheduled to present at the J.P. Morgan 33 Annual Healthcare Conference in San Francisco on Tuesday, January 13, 2015 at 2:30 p.m. PST.
JPM: 59.67 (+0.10), KPTI: 27.12 (-0.13)
Karyopharm Therapeutics prices public offering at USD33.00 per share
M2 - Wed Jan 07, 6:16AM CST
Pharmaceutical company Karyopharm Therapeutics (NasdaqGS:KPTI) said on Wednesday that it has priced its public offering of 3,000,000 shares of its common stock at USD33.00 per share before underwriting discounts.
KPTI: 27.12 (-0.13)
Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Tue Jan 06, 10:55PM CST
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) today announced the pricing of its underwritten public offering of 3,000,000 shares of its common stock at a price of $33.00 per share before underwriting discounts. Karyopharm is selling 2,950,000 shares of its common stock in this offering, and certain existing stockholders are selling 50,000 shares of common stock in this offering. Karyopharm will not receive any proceeds from the sale of shares by the selling stockholders. In addition, Karyopharm has granted to the underwriters a 30-day option to purchase up to an additional 450,000 shares of its common stock, at the public offering price, less the underwriting discount.
KPTI: 27.12 (-0.13)
Karyopharm Therapeutics to issue public offering of 3m common shares
M2 - Tue Jan 06, 4:39AM CST
Pharmaceutical company Karyopharm Therapeutics (NasdaqGS:KPTI) said on Monday that it plans to start an underwritten public offering of 3,000,000 shares of its common stock.
KPTI: 27.12 (-0.13)
Karyopharm commences secondary offering
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 4:18PM CST
KPTI: 27.12 (-0.13)
Karyopharm Therapeutics Announces Proposed Public Offering of Common Stock
GlobeNewswire - Mon Jan 05, 3:44PM CST
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) today announced that it has commenced an underwritten public offering of 3,000,000 shares of its common stock. The offering is expected to consist of 2,950,000 shares to be offered by Karyopharm and 50,000 shares to be offered by existing stockholders. Karyopharm will not receive any proceeds from the sale of shares by the selling stockholders. In addition, Karyopharm intends to grant the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
JPM: 59.67 (+0.10), KPTI: 27.12 (-0.13)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), FPRX: 24.63 (+0.63), ZFGN: 39.06 (+0.92), CRIS: 3.23 (+0.25), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Karyopharm Announces Addition to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 8:06AM CST
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced today that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq:NBI). The addition to the NASDAQ Biotechnology Index will become effective upon market open on Monday, December 22, 2014.
IBB: 323.46 (+3.04), KPTI: 27.12 (-0.13)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), ZGNX: 1.43 (+0.05), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), NDAQ: 49.48 (-0.27), FPRX: 24.63 (+0.63), CRIS: 3.23 (+0.25), ZFGN: 39.06 (+0.92), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Dec 11, 11:45AM CST
SD: 2.09 (+0.14), FRO: 2.96 (+0.07), ABCO: 53.69 (+0.32), ZAZA: 2.17 (+0.08), JMEI: 12.67 (+0.31), SGMO: 15.40 (+0.14), TGTX: 13.13 (-0.19), MEI: 39.40 (+0.22), WLT: 1.09 (+0.05), NSPR: 0.70 (-0.05), VII: 1.47 (-0.02), CVTI: 29.64 (-0.13), MEIP: 5.00 (-0.04), ALDR: 26.06 (+0.18), CALA: 16.11 (+0.62), CGG: 6.86 (+0.06), SPP: 1.36 (unch), DSCO: 1.43 (+0.05), KPTI: 27.12 (-0.13), HBOS: 24.84 (+0.14)
T-Cell Lymphomas - Pipeline Review, H2 2014
M2 - Thu Dec 11, 3:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/2wvfhz/tcell_lymphomas) has announced the addition of the "T-Cell Lymphomas - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for T-Cell Lymphomas, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for T-Cell Lymphomas and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for T-Cell Lymphomas - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding T-Cell Lymphomas pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - arGEN-X - Bristol-Myers Squibb - Celgene - Cell Medica - Infinity Pharmaceuticals - Karyopharm Therapeutics - Kyowa Hakko Kirin - Nippon Kayaku - Novartis - Ono Pharmaceutical - Onyx Pharmaceuticals - Pharma Mar - Pharmacyclics - Seattle Genetics - Sigma-Tau For more information visit http://www.researchandmarkets.com/research/2w..._lymphomas
INFI: 15.13 (+0.55), BMY: 60.04 (+0.56), NVS: 102.20 (-0.17), KPTI: 27.12 (-0.13), CELGZ: 3.17 (-0.04)
Weakness Seen in Karyopharm Therapeutics (KPTI): Stock Tanks 10% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 7:49AM CST
Make sure to keep an eye on Karyopharm Therapeutics going forward to see if this recent slump will continue, as the earnings picture definitely suggests that this might be the case.
KPTI: 27.12 (-0.13)
